

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

AUG 16 PM 3:38

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page


1. Registrant Name PodestaMattoon			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1001 G Street, NW Suite 900 East City Washington State/Zip (or Country) DC 20001			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Jeff Cordeau	Telephone 202-879-9366	E-mail (optional) jcordeau@podestamattoon.com	5. Senate ID # 31680-381
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research & Manufacturers of America			6. House ID # 31110-014

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐ >> Termination Date _____11. No Lobbying Activities ☐**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$180,000.00</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6033 of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

James J. Cordeau
Filing #2708679a-fd5d-44a0-984f-a5f19383e51e - Page 1 of 8

Date 7/19/2004

Signature  Date 02/27/2021

Printed Name and Title Sharon Cohen - Principal P:

Registrant Name: PodestaMattoon

Client Name: Pharmaceutical Research & Manufacturers of America

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

H.R.2769, Save Our Seniors Act of 2003 ,

S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard.

S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004,

S.2493 Safe IMPORT Act of 2004

Implementation of H.R.1 Medicare Prescription Drug and Modernization Act of 2003

FDA Drug Approval Issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

Executive Office of the President

House of Representatives

Office of the Vice President

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ahearn, Alison	
Cohen, Sharon	
Hastert, Joshua	
Mattoon, Daniel J.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date **7/19/2004**

Signature [Signature] Date

Printed Name and Title Sharon Cohen - Principal Page

Registrant Name: **PodestaMattoon**

Client Name: **Pharmaceutical Research & Manufacturers of America**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MMM** (one per page)

16. Specific Lobbying issues

H.R.2769, Save Our Seniors Act of 2003 ,

S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard

S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004,

S.2493 Safe IMPORT Act of 2004

Implementation of H.R.1 Medicare Prescription Drug and Modernization Act of 2003

FDA Drug Approval Issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

Executive Office of the President

House of Representatives

Office of the Vice President

Senate


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ahearn, Alison	
Cohen, Sharon	
Hastert, Joshua	
Mattoon, Daniel J.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

James S. Podesta

Signature  Date 11/12/2007

Printed Name and Title Sharon Cohen - Principal Pg

Registrant Name: **PodestaMattoon**

Client Name: **Pharmaceutical Research & Manufacturers of America**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **PHA** (one per page)

16. Specific Lobbying issues

H.R.2769, Save Our Seniors Act of 2003 ,

S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard;

S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004,

S.2493, Safe IMPORT Act of 2004 ,

Implementation of H.R.1 Medicare Prescription Drug and Modernization Act of 2003

FDA Drug Approval Issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

Executive Office of the President

House of Representatives

Office of the Vice President

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ahearn, Alison	
Cohen, Sharon	
Hastert, Joshua	
Mattoon, Daniel J.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Kevin S. Loh

Signature _____ Date _____

Printed Name and Title Sharon Cohen - Principal P